News
Terns has a further Phase 2 ready asset in TERN-501, which is a thyroid hormone receptor beta (THR-β) agonist being developed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback